Cell line · CVCL_1417
MKN7
Cancer cell line, Homo sapiens. Gastric tubular adenocarcinoma. 36 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. MKN7. Cell lines, record CVCL_1417. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1417
On this page
Cell line
As Cellosaurus gives it.
- Name
- MKN7
- Accession
- CVCL_1417
- RRID
- RRID:CVCL_1417
- Synonyms
- MKN-7, MKN 7
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 39Y
- Category
- Cancer cell line
- Diseases
- Gastric tubular adenocarcinoma (NCIt C5473)
- Derived from
- Lymph node (metastatic)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems1
| Problem | Cellosaurus's note |
|---|---|
| Caution | TP53 mutation indicated incorrectly as being at p.Ile251Leu (c.751A>C) in PubMed=15900046. |
Source Cellosaurus
Papers36
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| PTTG1 drives intestinal-type gastric cancer progression via G2/M checkpoint-mediated cell-cycle reprogramming. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MTSS1-dependent ubiquitin modifications mediated by FBXO44 remodel the actin cytoskeleton to promote gastric cancer progression. | Mol Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Machine learning-based development of a cytotoxicity prediction model for NK cell therapy in cancers. | Cell Oncol (Dordr) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Acquired vulnerability against EGF receptor inhibition in gastric cancer promoted by class I histone deacetylase inhibitor entinostat. | Neoplasia | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer. | Sci Rep | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. | Clin Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| FARP1 boosts CDC42 activity from integrin αvβ5 signaling and correlates with poor prognosis of advanced gastric cancer. | Oncogenesis | 2020 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 36
See all 36 papersRelatives1
| Relation | Cell line | Accession | Problem |
|---|---|---|---|
| Derived from it | MKN7/CMV-Luc | CVCL_4Y05 |
Source Cell lines
Cell banks7
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| CLS | 305104 | CLS | |
| JCRB | FDSC0010 | Discontinued | Cellosaurus |
| JCRB | JCRB0082 | Discontinued | Cellosaurus |
| JCRB | JCRB1025 | JCRB | |
| RCB | RCB0999 | RCB | |
| RCB | RCB3687 | RCB | |
| TKG | TKG 0228 | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1417
GET https://conductscience.org/api/cell-lines/v1/CVCL_1417/papers?page=2